Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study

G Lopes; YL Wu; I Kudaba; D Kowalski; BC Cho; G Castro; V Srimuninnimit; I Bondarenko; K Kubota; GM Lubiniecki; J Zhang; DA Kush; T Mok

doi:10.1200/JCO.2018.36.18_suppl.LBA4

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study

G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, V Srimuninnimit, I Bondarenko, K Kubota, GM Lubiniecki, J Zhang, DA Kush, T Mok

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	LBA4
Journal	Journal of Clinical Oncology
Volume	36
Issue number	18, Suppl.
DOIs	https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4
Publication status	Published - 20 Jun 2018
Externally published	Yes
Event	2018 American Society of Clinical Oncology (ASCO) Annual Meeting - Chicago, United States Duration: 1 Jun 2018 → 5 Jun 2018

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1200/JCO.2018.36.18_suppl.LBA4

Cite this

Lopes, G., Wu, YL., Kudaba, I., Kowalski, D., Cho, BC., Castro, G., Srimuninnimit, V., Bondarenko, I., Kubota, K., Lubiniecki, GM., Zhang, J., Kush, DA., & Mok, T. (2018). Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study. Journal of Clinical Oncology, 36(18, Suppl.), [LBA4]. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4

@article{050952068c8d4b758fc51a7da5ab10d7,

title = "Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study",

author = "G Lopes and YL Wu and I Kudaba and D Kowalski and BC Cho and G Castro and V Srimuninnimit and I Bondarenko and K Kubota and GM Lubiniecki and J Zhang and DA Kush and T Mok",

year = "2018",

month = jun,

day = "20",

doi = "10.1200/JCO.2018.36.18_suppl.LBA4",

language = "English",

volume = "36",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "18, Suppl.",

note = "2018 American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 01-06-2018 Through 05-06-2018",

}

Lopes, G, Wu, YL, Kudaba, I, Kowalski, D, Cho, BC, Castro, G, Srimuninnimit, V, Bondarenko, I, Kubota, K, Lubiniecki, GM, Zhang, J, Kush, DA & Mok, T 2018, 'Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study', Journal of Clinical Oncology, vol. 36, no. 18, Suppl., LBA4. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1% : Open-label, phase 3 KEYNOTE-042 study. / Lopes, G; Wu, YL; Kudaba, I et al.

In: Journal of Clinical Oncology, Vol. 36, No. 18, Suppl., LBA4, 20.06.2018.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%

T2 - 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

AU - Lopes, G

AU - Wu, YL

AU - Kudaba, I

AU - Kowalski, D

AU - Cho, BC

AU - Castro, G

AU - Srimuninnimit, V

AU - Bondarenko, I

AU - Kubota, K

AU - Lubiniecki, GM

AU - Zhang, J

AU - Kush, DA

AU - Mok, T

PY - 2018/6/20

Y1 - 2018/6/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000443284700005&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/JCO.2018.36.18_suppl.LBA4

DO - 10.1200/JCO.2018.36.18_suppl.LBA4

M3 - Meeting Abstract

SN - 0732-183X

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 18, Suppl.

M1 - LBA4

Y2 - 1 June 2018 through 5 June 2018

ER -

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this